Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13474406 | 0.87 | AGTR1 (0.51) | AGTR1AGTR2 | |
| SCHEMBL2796345 | 0.85 | AGTR1 (0.70) | AGTR1AGTR2 | |
| SCHEMBL588365 | 0.85 | AGTR1 (0.41) | AGTR1AGTR2 | |
| SCHEMBL15336224 | 0.81 | AGTR1 (0.72) | AGTR1AGTR2 | |
| SCHEMBL8972186 | 0.80 | AGTR2 (0.59) | AGTR1AGTR2 | |
| SCHEMBL2796231 | 0.79 | AGTR1 (0.52) | AGTR1AGTR2 | |
| SCHEMBL4250985 | 0.78 | AGTR1 (0.49) | AGTR1AGTR2 | |
| SCHEMBL9448440 | 0.78 | AGTR1 (0.46) | AGTR1AGTR2 | |
| SCHEMBL9844033 | 0.78 | AGTR1 (0.50) | AGTR1AGTR2 | |
| SCHEMBL1773521 | 0.78 | FYN (0.39) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162441-B1 | 1,(3,)5-substituted imidazoles, useful in the treatment of hypertension and methods for their preparation | ELDRUG S A (GR) | 2016-01-06 | — | — | EP | disclosed |
| US-8563586-B2 | 1,(3,)5-substituted imidazoles, their use in the treatment of hypertension and methods for their preparation | ELDRUG S.A. (GR) | 2013-10-22 | — | — | US | disclosed |
| US-20100166837-A1 | 1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION | ELDRUG S.A. (GR) | 2010-07-01 | — | — | US | disclosed |
| EP-2162441-A2 | 1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION | Eldrug S.A. (GR) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008142576-A2 | 1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION | ELDRUG S.A. (GR) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166837-A1 | 1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION | AGTR1, AGTR2, AGT | AGTR1 1/4885AGTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.